移植前冠心病检查与肾移植早期结局的关联
该回顾性队列纳入2000年1月至2014年12月美国肾脏数据系统中79 334例成人首次肾移植受者,采用工具变量分析,以移植当年项目层面冠心病检查率作为工具变量。主要终点为移植后30天内死亡或急性心梗复合终点,共发生4604例(244例[5.3%];死亡120例[2.6%],急性心梗134例[2.9%])。主工具变量分析中,与未检查相比,冠心病检查与主要终点率变化无关(率差1.9%;95%CI 0%-3.5%);2000至2003年期间冠心病检查与更高事件率相关(率差6.8%;95%CI 1.8%-12.0%)。作者认为该结果提示移植前冠心病检查未降低早期死亡或急性心梗,可能挑战其普遍应用,并应在干预性研究中确认。
要点
- 主工具变量分析:与未检查相比,移植前冠心病检查与30天内死亡或急性心梗复合终点率变化无关(率差1.9%;95%CI 0%-3.5%)。
- 2000至2003年期间,冠心病检查与更高事件率相关(率差6.8%;95%CI 1.8%-12.0%)。
- 2012至2014年,检查最密集项目(工具变量第五分位)冠心病检查率为56%,最不密集项目(第一分位)为24%(P < .001)。
- 主要终点共4604例(244例[5.3%]):死亡120例(2.6%),急性心梗134例(2.9%)。
- 作者认为移植前冠心病检查未降低早期死亡或急性心梗,可能挑战其普遍应用,并应在干预性研究中确认。
适用人群与场景
- 2000年1月至2014年12月美国肾脏数据系统中所有成人首次肾移植受者,移植前后各有至少1年Medicare参保。
- 队列共79 334例:女性30 147例(38%);黑人25 387例(21%),白人48 394例(61%);2012至2014年平均(SD)年龄56(14)岁。
处置流程与药物剂量
- 暴露定义为肾移植前12个月内接受非紧急侵入性或无创性冠心病检查。
研究设计与关键结果
- 研究类型:回顾性队列研究,采用工具变量分析,以移植当年项目层面冠心病检查率作为工具变量,并按研究时期分层。
- 主要终点为肾移植后30天内死亡或急性心梗复合终点,共发生4604例(244例[5.3%];死亡120例[2.6%],急性心梗134例[2.9%])。
- 2012至2014年,检查最密集项目(工具变量第五分位)冠心病检查率为56%,最不密集项目(第一分位)为24%(P < .001),其他研究时期模式相似。
- 主工具变量分析中,与未检查相比,冠心病检查与主要终点率变化无关(率差1.9%;95%CI 0%-3.5%)。
- 各研究时期结果相似,但2000至2003年期间冠心病检查与更高事件率相关(率差6.8%;95%CI 1.8%-12.0%)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,移植前冠心病检查与早期移植后死亡或急性心梗减少无关,该发现可能挑战肾移植前普遍进行冠心病检查的做法,并应在干预性研究中确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Testing for coronary heart disease (CHD) in asymptomatic kidney transplant candidates before transplant is widespread and endorsed by various professional societies, but its association with perioperative outcomes is unclear.
OBJECTIVE: To estimate the association of pretransplant CHD testing with rates of death and myocardial infarction (MI).
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included all adult, first-time kidney transplant recipients from January 2000 through December 2014 in the US Renal Data System with at least 1 year of Medicare enrollment before and after transplant. An instrumental variable (IV) analysis was used, with the program-level CHD testing rate in the year of the transplant as the IV. Analyses were stratified by study period, as the rate of CHD testing varied over time. A combination of US Renal Data System variables and Medicare claims was used to ascertain exposure, IV, covariates, and outcomes.
EXPOSURES: Receipt of nonurgent invasive or noninvasive CHD testing during the 12 months preceding kidney transplant.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death or acute MI within 30 days of after kidney transplant.
RESULTS: The cohort comprised 79 334 adult, first-time kidney transplant recipients (30 147 women [38%]; 25 387 [21%] Black and 48 394 [61%] White individuals; mean [SD] age of 56 [14] years during 2012 to 2014). The primary outcome occurred in 4604 patients (244 [5.3%]; 120 [2.6%] death, 134 [2.9%] acute MI). During the most recent study period (2012-2014), the CHD testing rate was 56% in patients in the most test-intensive transplant programs (fifth IV quintile) and 24% in patients at the least test-intensive transplant program (first IV quintile, P < .001); this pattern was similar across other study periods. In the main IV analysis, compared with no testing, CHD testing was not associated with a change in the rate of primary outcome (rate difference, 1.9%; 95% CI, 0%-3.5%). The results were similar across study periods, except for 2000 to 2003, during which CHD testing was associated with a higher event rate (rate difference, 6.8%; 95% CI, 1.8%-12.0%).
CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that pretransplant CHD testing was not associated with a reduction in early posttransplant death or acute MI. The study findings potentially challenge the ubiquity of CHD testing before kidney transplant and should be confirmed in interventional studies.
参考来源
- Cheng XS, Liu S, Han J, et al. Association of Pretransplant Coronary Heart Disease Testing With Early Kidney Transplant Outcomes. JAMA Intern Med. 2023. PMID: 36595271. doi:10.1001/jamainternmed.2022.6069
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。